Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Incyte to Use IBM Software in New Platform

This story has been updated from an early version with comments from IBM, Incyte

NEW YORK, Sept 11 - Incyte Genomics (Nasdaq: INCY) of Palo Alto, Calif., said Monday it would incorporate IBM’s (NYSE: IBM) data management software into its new genomic research tool.

The deal represents IBM’s first partnership with the genomics industry since announcing in August that it would make an investment of $100 million in the life sciences over the next two and a half years.

“Under this agreement, DiscoveryLink is an embedded component in the new Incyte architecture,” said vice president of IBM’s life sciences division Caroline Kovac.

IBM of Somer, NY, hopes that the integration of its data management software into all of Incyte’s products will move the platform a step closer to becoming the industry standard.

“By integrating DiscoveryLink right into the Incyte product … DiscoveryLink is automatically going right into the heart of bioinformatics at the world’s major pharmaceutical companies,” said Incyte Chairman Randy Scott. “We’ve already got some software developers that are agreeing to write to the platform.”   

Kovac and Scott declined to disclose terms of the deal.

Incyte’s Genomic Knowledge Platform is designed to analyze complex biological systems, while IBM’s software is geared to help researchers integrate genomic analysis tools and diverse data sets, such as DNA sequence, gene expression, proteomics, and genetic variations.

Using Genomic Knowledge Platform with DiscoveryLink, researchers can run a single query against multiple databases and get one integrated view of information, Incyte said.

" DiscoveryLink is a key component of our genomic knowledge platform, which breaks down a major barrier to scientific discovery -- mining the increasing amounts of genomic, chemical and clinical information," Roy Whitfield, CEO of Incyte, said in a statement.

Incyte develops genomic technologies designed to enable researchers to understand the molecular basis of disease. The company also makes and markets genomic databases, data management software, microarry-based gene expression services, and related reagents.

 

 

 

 

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.